Does smoking change the efficacy of combination therapy with vitamin E and colchicines in patients with early-stage Peyronie's disease?


Cakan M., Demirel F., Aldemir M., Altug U.

ARCHIVES OF ANDROLOGY, cilt.52, ss.21-27, 2006 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 52 Konu: 1
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1080/01485010500302014
  • Dergi Adı: ARCHIVES OF ANDROLOGY
  • Sayfa Sayısı: ss.21-27

Özet

This study was conducted to find out if smoking has an effect on the results of combination therapy with vitamin E and colchicines in patients with early-stage Peyronie's disease (PD). A total of 58 potent Patients suffering from early-stage PD were included in the study (mean age 47.3 years, range 25-73 y). The time from onset of the disease was <6 months and no patient had ED. The patients with severe fibrotic or calcified plaques were not included in the study. Of the patients, 36 were smokers (Group 1) and 22 were non-smokers (Group 2). All the patients received vitamin E (800 X daily) and colchicines (1 mg daily) for 6 months. Follow-up) ranged from 5 to 13 months (mean 10.3m). The combination therapy was effective and well tolerated in both groups. There were no significant differences between the two groups according to age, disease duration, related disease (diabetes, hypertension, hypercholesterolemia, and hypertriglyceridemia), plaque sizes, and plaque numbers. The resolution in pain and increase in penile curvature and plaque size were similar rates in both groups (p > 0.05), while decrease in penile curvature and plaque size were higher in Group 2 (p <0.05). No patient discounted the therapy due to side effects. The oral combination therapy with vitamin E and colchicines appears to be an effective procedure in patients with early-stage PD and smoking may have worsening effects on the treatment results.